Our results encourage the further evaluation of the prognostic significance of high-level ERBB1 mRNA expression and the clinical potential of ERBB1-targeting therapeutics as personalized medicines in high-risk DLBCL. The gene discussed is EGFR; the disease is diffuse large B-cell lymphoma.